PHD finger protein 19 (PHF19) (PHF19)

PHD finger protein 19 (PHF19), also known as PCL3, is a member of the Polycomb-like family and a critical accessory component of the Polycomb Repressive Complex 2 (PRC2) (UniProt, 2024; Q8WV24). It functions as an epigenetic reader that specifically recognizes trimethylated histone H3 lysine 36 (H3K36me3) through its Tudor domain, thereby recruiting the PRC2 complex to specific genomic loci to catalyze H3K27 trimethylation and mediate gene silencing (Vizán et al., 2015; PMID: 25601757). PHF19 is essential for maintaining the proliferative capacity of embryonic stem cells and plays a significant role in cell cycle regulation and hematopoietic differentiation (Ballaré et al., 2012; PMID: 22325148). In various malignancies, particularly multiple myeloma and prostate cancer, PHF19 is frequently overexpressed and serves as a driver of aggressive disease phenotypes and poor clinical outcomes (Mason et al., 2020; PMID: 32439612). Therapeutic development targeting PHF19 includes the use of antisense oligonucleotides to degrade PHF19 mRNA and small molecule inhibitors designed to disrupt the interaction between its Tudor domain and histone marks (Ren et al., 2018; PMID: 30104398). These interventions aim to restore the expression of tumor suppressor genes and halt the progression of PHF19-dependent cancers.

Other names

PCL3Polycomb-like protein 3hPCL3DPHF19PHD finger protein 19 mRNA

Antisense oligonucleotides (ASOs) bind to PHF19 mRNA, leading to its degradation by RNase H, which reduces PHF19 protein levels and prevents the recruitment of the Polycomb Repressive Complex 2 (PRC2) to H3K36me3-marked chromatin, thereby inhibiting the silencing of tumor suppressor genes (Mason et al., 2020; PMID: 32439612). Small molecule inhibitors target the Tudor domain of PHF19 to competitively inhibit its binding to H3K36me3, disrupting the epigenetic regulation required for cancer cell proliferation (Ren et al., 2018; PMID: 30104398).